Yayınlar & Eserler

Yayın Ağı
Makaleler 27
Tümü (27)
SCI-E, SSCI, AHCI (24)
SCI-E, SSCI, AHCI, ESCI (27)
ESCI (2)
Scopus (26)
TRDizin (5)

1. Improved detection of advanced fibrosis using a metabolically informed model in the MASLD era: comparison with FIB-4

UYGUR M. M., Yazman V., Gul A. N., Keskin I., Uygur O., KEKLİKKIRAN Ç.
EUROPEAN JOURNAL OF ENDOCRINOLOGY , cilt.195, 2026 (SCI-Expanded, Scopus)

2. Limited agreement between FibroScan and MR-based assessment of hepatic steatosis and fibrosis in acromegaly: a proof-of-concept study

UYGUR M. M., Gul A. N., TÜFEKÇİ D., BURAKGAZİ G., KEKLİKKIRAN Ç.
EUROPEAN JOURNAL OF ENDOCRINOLOGY , cilt.195, 2026 (SCI-Expanded, Scopus)

3. TASL practice guidance for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease (MASLD)

YILMAZ Y., Adali G., Ergenc I., Kaya E., TURAN GÖKÇE D., KEKLİKKIRAN Ç., et al.
HEPATOLOGY FORUM , cilt.7, sa.3, ss.177-214, 2026 (ESCI, Scopus, TRDizin) Creative Commons License

4. The Relationship Between Adherence to the Mediterranean Diet, Oxidative Stress, Trimethylamine N-Oxide, and Inflammatory Markers in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

Kazdal S. M., ARPA M., KEKLİKKIRAN Ç., YÜCECAN S.
NUTRIENTS , cilt.18, sa.14, 2026 (SCI-Expanded, Scopus)

5. Blood Urea Nitrogen to Serum Albumin Ratio Is Associated with MASH and Significant Fibrosis: Report from a Turkish Biopsy-Proven MASLD Cohort

Kirik A., Kaya E., Keklikkiran C., Yilmaz Y.
JOURNAL OF CLINICAL MEDICINE , cilt.15, sa.15, 2026 (SCI-Expanded, Scopus)

6. Metabolic dysfunction-associated steatotic liver disease in cushing's syndrome: a case controlled FibroScan study

Apaydin T., Keklikkiran C., KANİ H. T., YILMAZ Y., YAVUZ D.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION , 2026 (SCI-Expanded, Scopus)

7. Spleen stiffness predicts clinical event-free survival in primary biliary cholangitis: a prospective cohort study

Ergenc I., Yapici H. B., KEKLİKKIRAN Ç., DEMİRTAŞ C. Ö., Kani H., Heneghan M., et al.
JOURNAL OF HEPATOLOGY , cilt.84, 2026 (SCI-Expanded, Scopus)

8. Fibrosis-4 Score and Postoperative Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease

EREN F., GÖKTUĞ M. R., Ari D., Ozkumur G. F., Bulbuller E. N., Gencdal G., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.37, sa.1, 2026 (SCI-Expanded, Scopus, TRDizin)

9. Prevalence and Clinical Associations of Malnutrition and Sarcopenia Risk in Gastroenterology Inpatients: A Multicenter Cross-Sectional Study in Turkey

BENGİ G., DOLU S., Ozden Y., Oruc N., Tozlu M., Hakim G. D., et al.
DIAGNOSTICS , cilt.15, sa.22, 2025 (SCI-Expanded, Scopus)

10. Usefulness of Endoscopic Ultrasound Strain Elastography for Measuring Liver Stiffness and the Role of Blood Cytokeratin 18 Levels as a Surrogate Marker of Fibrosis

Duman D. G., Alahdab Y. O., DEMİRTAŞ C. Ö., YILMAZ Y., Dilber F., Ozdemir F. T., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.36, sa.10, 2025 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

11. Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry

YILMAZ Y., Keklikkiran Ç., Racila A., Stepanova M., Younossi Z.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY , cilt.16, sa.6, 2025 (SCI-Expanded, Scopus)

12. Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1

Karatas F. N., Keklikkıran Ç., Yılmaz Y., Ay N. P., Korten V., Sili U.
CURRENT HIV RESEARCH , cilt.23, sa.2, ss.121-132, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

13. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease

Younossi Z. M., AlQahtani S. A., Funuyet-Salas J., Romero-Gómez M., YILMAZ Y., Keklikkiran Ç., et al.
JHEP REPORTS , cilt.6, sa.7, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. Prevalence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis in Türkiye: A forensic autopsy study

Ergenc I., Kara E., Yilmaz M. E., DEMİRTAŞ C. Ö., Keklikkiran Ç., Das T., et al.
HELIYON , cilt.10, sa.14, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

15. Diagnostic accuracy of AGILE 3+score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis

Dalbeni A., Lombardi R., Henrique M., Zoncape M., Pennisi G., Petta S., et al.
HEPATOLOGY , cilt.79, sa.5, ss.1107-1116, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

16. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

Younossi Z. M., Alqahtani S. A., Alswat K., YILMAZ Y., Keklikkiran Ç., Funuyet-Salas J., et al.
JOURNAL OF HEPATOLOGY , cilt.80, sa.3, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

17. Can Frequent Toothbrushing Reduce the Risk of Cirrhosis among Patients with Non-alcoholic Fatty Liver Disease? Hints from a Registry-based Study

Keklikkiran Ç., Stepanova M., Younossi Z., Yilmaz Y.
DIGESTIVE DISEASES , cilt.41, sa.6, ss.932-937, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

18. The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients

ERGENÇ İ., Gozaydinoglu B., KEKLİKKİRAN Ç., YILMAZ Y.
Hepatology forum , cilt.4, sa.2, ss.69-73, 2023 (TRDizin) Creative Commons License

19. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study

Yilmaz Y., Toraman A. E., Alp C., Doğan Z., Keklikkiran Ç., Stepanova M., et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.57, sa.2, ss.215-223, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Global multi-stakeholder endorsement of the MAFLD definition

Méndez-Sánchez N., Bugianesi E., Gish R. G., Lammert F., Tilg H., Nguyen M. H., et al.
The Lancet Gastroenterology and Hepatology , cilt.7, sa.5, ss.388-390, 2022 (SCI-Expanded, Scopus)

21. Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study

Demirtas C. O., Keklikkiran Ç., Ergenc I., Erturk Sengel B., Eskidemir G., Cinel I., et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

22. Causes of erectile dysfunction in non-alcoholic fatty liver disease

KANİ H. T., ŞENER T. E., Aykut U. E., DEMİRTAŞ C. Ö., Keklikkiran Ç., Ergenc I., et al.
HEPATOLOGY FORUM , cilt.2, sa.2, ss.60-63, 2021 (ESCI, Scopus) Sürdürülebilir Kalkınma

23. Recommendations for Reopening Endoscopy Units in Turkey: A Set-up Plan from a Tertiary Center in Istanbul.

Demirtas C. Ö., Keklikkıran Ç., Mehdiyev S., Ergenç İ., Özen Alahdab Y., Gündüz F., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.32, ss.113-115, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

24. Evaluation of the Association between Programmed Cell Death-1 Gene Polymorphisms and Hepatocellular Carcinoma Susceptibility in Turkish Subjects. A Pilot Study

Demirci A. F., Demirtas C. O., Eren F., Yilmaz D., Keklikkiran Ç., Ozdogan O. C., et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES , cilt.29, sa.4, ss.617-622, 2020 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

25. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients

Demirtas C., Gunduz F., Kani H., Keklikkıran Ç., Alahdab Y., Yılmaz Y., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.32, sa.7, ss.882-888, 2020 (SCI-Expanded, Scopus)

26. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.

Kaya E., Bakir A., Kani H., Demirtas C., Keklikkiran Ç., Yilmaz Y.
Gut and liver , cilt.14, ss.486-491, 2020 (SCI-Expanded, Scopus)

27. Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study.

Bilgin B., Sunbul M., Kani H. T., Demirtas C., Keklikkiran Ç., Yilmaz Y.
European journal of gastroenterology & hepatology , cilt.32, ss.54-57, 2020 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 8

1. Gender differences in stigma and care avoidance among people living with metabolic dysfunction-associated steatotic liver disease (MASLD): an international survey

Carrieri P., Zelber-Sagi S., Alqahtani S., Al Naamani K., Yilmaz Y., Keklikkiran C., et al.
Congress of the European-Association-for-the-Study-of-the-Liver Congress (EASL), Barcelona, İspanya, 27 - 30 Mayıs 2026, cilt.84, (Özet Bildiri)

2. Obstrüktif Uyku Apne Sendromlu Hastalarda Non-Alkolik Yağlı Karaciğer Hastalığının Değerlendirilmesi

Özyurt S., Keklikkıran Ç., Yılmaz Kara B., Özçelik N., Gümüş A., Şahin Ü., et al.
UASK 2025, Antalya, Türkiye, 9 - 12 Nisan 2025, (Özet Bildiri)

3. Pruritus and fatigue in patients with metabolic dysfunction associated steatotic liver disease (MASLD):Data from the Global NASH/MASH Registry

Yılmaz Y., Keklikkıran Ç., Racila A., Stepanova M., Younossi Z.
APASL Congress 2025, Beijing, Çin, 26 - 31 Mart 2025, ss.1, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

4. PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) HAVE SIMILAR CLINICAL, NON-INVASIVE TESTS ( NITS) AND PATIENT-REPORTED OUTCOMES (PROS) PROFILE

Younossi Z., YILMAZ Y., Yu L., Isakov V., Fernandez M. I. C., Wong V., et al.
The Liver Meeting, California, Amerika Birleşik Devletleri, 15 - 19 Kasım 2024, cilt.80, (Özet Bildiri)

5. FATIGUE IN CHRONIC HEPATITIS B (CHB) AND C (CHC) IS ASSOCIATED WITH IMPAIRMENT OF PATIENT-REPORTED OUTCOMES (PROS) AND WORK PRODUCTIVITY

YILMAZ Y., Yu M., Alswat K., El-Kassas M., Buti M., Papatheodoridis G., et al.
The Liver Meeting, California, Amerika Birleşik Devletleri, 15 - 19 Kasım 2024, cilt.80, (Özet Bildiri)

6. THE IMPACT OF SUPERIMPOSED METABOLICDYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE ( MASLD) ON CLINICAL AND PATIENT- REPORTED OUTCOMES ( PROS) PROFILE OF PATIENTS WITH CHRONIC HEPATITIS B ( CHB) AND C ( CHC)

Younossi Z., Buti M., Papatheodoridis G., YILMAZ Y., Yu M., El-Kassas M., et al.
The Liver Meeting, California, Amerika Birleşik Devletleri, 15 - 19 Kasım 2024, cilt.80, (Özet Bildiri)

7. Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Younossi Z., YILMAZ Y., Yu M., Isakov V., Fernández M. I. C., Wong V. W., et al.
EASL Congress 2024, Milan, İtalya, 05 Haziran 2024, cilt.80, ss.643, (Tam Metin Bildiri)

8. Transient elastography measurements of spleen stiffness are associated with treatment response to ursodeoxycholic acid in primary biliary cholangitis

ERGENÇ İ., YAPICI H., KEKLİKKIRAN Ç., YILMAZ Y.
International Liver Congress (EASL) 2023, Avusturya, 21 - 24 Haziran 2023, cilt.78, ss.389-390, (Tam Metin Bildiri)
Metrikler

Yayın

36

Yayın (WoS)

32

Yayın (Scopus)

27

Atıf (WoS)

540

H-İndeks (WoS)

9

Atıf (Scopus)

540

H-İndeks (Scopus)

8

Atıf (Scholar)

5

H-İndeks (Scholar)

1

Atıf (TrDizin)

3

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

3

Proje

2

Açık Erişim

3
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER